DelveInsight’s, “Psoriasis Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Psoriasis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Psoriasis Pipeline Outlook
Key Takeaways from the Psoriasis Pipeline Report
- In April 2025, Alumis Inc. announced a study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001. Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks.
- DelveInsight’s Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.
- The leading Psoriasis Companies such as Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals and others.
- Promising Psoriasis Pipeline Therapies such as Hypericin, Cetaphil, EDP1815, AX-158, Calcipotriol, MP1032, Risankizumab, Certolizumab Pegol, and others.
Stay ahead with the most recent pipeline outlook for Psoriasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Psoriasis Treatment Drugs
Psoriasis Emerging Drugs Profile
- Topical roflumilast: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.
- GSK2982772: GlaxoSmithKline
GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.
The Psoriasis Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
- Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market
Explore groundbreaking therapies and clinical trials in the Psoriasis Pipeline. Access DelveInsight’s detailed report now! @ New Psoriasis Drugs
Psoriasis Companies
Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals and others.
Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical.
- Molecule Type
Psoriasis Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Unveil the future of Psoriasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Psoriasis Market Drivers and Barriers
Scope of the Psoriasis Pipeline Report
- Coverage- Global
- Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals and others.
- Psoriasis Pipeline Therapies- Hypericin, Cetaphil, EDP1815, AX-158, Calcipotriol, MP1032, Risankizumab, Certolizumab Pegol, and others.
- Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Psoriasis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Psoriasis Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Psoriasis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Psoriasis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Psoriasis Collaboration Deals
- Late Stage Products (Phase III)
- CT-P43: Celltrion
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- EDP1815: Evelo Biosciences
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AZD0284: AstraZeneca
- Drug profiles in the detailed report…..
- Early Stage Products (Preclinical)
- AZD0284: AstraZeneca
- Drug profiles in the detailed report…..
- Inactive Products
- Psoriasis Key Companies
- Psoriasis Key Products
- Psoriasis- Unmet Needs
- Psoriasis- Market Drivers and Barriers
- Psoriasis- Future Perspectives and Conclusion
- Psoriasis Analyst Views
- Psoriasis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market